Abstract
Relationships between apolipoproteins and other lipid parameters and cardiovascular (CV) prognosis were evaluated in the Angina Prognosis Study In Stockholm (APSIS). Out of 809 patients with stable angina pectoris, lipid variables were obtained in 786 patients at baseline, and after one month's double-blind treatment with metoprolol or verapamil, to evaluate treatment effects on these lipid variables. During a median follow-up time of 3.3 years (2663 patient years), 37 patients suffered a CV death, 30 suffered a non- fatal myocardial infarction (MI) and 100 underwent a revascularization. Apolipoprotein (apo) A-I, high-density lipoprotein cholesterol and triglycerides were predictors of CV death or non-fatal MI in univariate analyses, but only apo A-I remained as an independent predictor in multivariate analyses. All lipid variables except low density lipoprotein cholesterol were related to the risk of revascularization in univariate analyses, but only apo A-I and apo B were independent predictors of such events. Triglycerides were weakly, but not independently, associated with prognosis. Verapamil and metoprolol had differential short-term effects on lipids, with a shift towards a more atherogenic profile in metoprolol treated patients. However, there was no significant impact of the treatment given, or of these treatment effects on the risk of CV events. Results of the present study suggest that apolipoprotein levels were better predictors of CV events than other lipid parameters in patients with stable angina pectoris.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 109-118 |
| Number of pages | 10 |
| Journal | Atherosclerosis |
| Volume | 135 |
| Issue number | 1 |
| DOIs | |
| State | Published - Nov 1997 |
| Externally published | Yes |
Fingerprint
Keywords
- Angina pectoris
- Apolipoproteins
- Lipoproteins
- Prognosis
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol : Results from the Angina Prognosis Study In Stockholm (APSIS). / Held, Claes; Hjemdahl, Paul; Rehnqvist, Nina; Björkander, Inge; Forslund, Lennart; Brodin, Ulf; Berglund, Lars; Angelin, Bo.
In: Atherosclerosis, Vol. 135, No. 1, 11.1997, p. 109-118.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cardiovascular prognosis in relation to apolipoproteins and other lipid parameters in patients with stable angina pectoris treated with verapamil or metoprolol
T2 - Results from the Angina Prognosis Study In Stockholm (APSIS)
AU - Held, Claes
AU - Hjemdahl, Paul
AU - Rehnqvist, Nina
AU - Björkander, Inge
AU - Forslund, Lennart
AU - Brodin, Ulf
AU - Berglund, Lars
AU - Angelin, Bo
PY - 1997/11
Y1 - 1997/11
N2 - Relationships between apolipoproteins and other lipid parameters and cardiovascular (CV) prognosis were evaluated in the Angina Prognosis Study In Stockholm (APSIS). Out of 809 patients with stable angina pectoris, lipid variables were obtained in 786 patients at baseline, and after one month's double-blind treatment with metoprolol or verapamil, to evaluate treatment effects on these lipid variables. During a median follow-up time of 3.3 years (2663 patient years), 37 patients suffered a CV death, 30 suffered a non- fatal myocardial infarction (MI) and 100 underwent a revascularization. Apolipoprotein (apo) A-I, high-density lipoprotein cholesterol and triglycerides were predictors of CV death or non-fatal MI in univariate analyses, but only apo A-I remained as an independent predictor in multivariate analyses. All lipid variables except low density lipoprotein cholesterol were related to the risk of revascularization in univariate analyses, but only apo A-I and apo B were independent predictors of such events. Triglycerides were weakly, but not independently, associated with prognosis. Verapamil and metoprolol had differential short-term effects on lipids, with a shift towards a more atherogenic profile in metoprolol treated patients. However, there was no significant impact of the treatment given, or of these treatment effects on the risk of CV events. Results of the present study suggest that apolipoprotein levels were better predictors of CV events than other lipid parameters in patients with stable angina pectoris.
AB - Relationships between apolipoproteins and other lipid parameters and cardiovascular (CV) prognosis were evaluated in the Angina Prognosis Study In Stockholm (APSIS). Out of 809 patients with stable angina pectoris, lipid variables were obtained in 786 patients at baseline, and after one month's double-blind treatment with metoprolol or verapamil, to evaluate treatment effects on these lipid variables. During a median follow-up time of 3.3 years (2663 patient years), 37 patients suffered a CV death, 30 suffered a non- fatal myocardial infarction (MI) and 100 underwent a revascularization. Apolipoprotein (apo) A-I, high-density lipoprotein cholesterol and triglycerides were predictors of CV death or non-fatal MI in univariate analyses, but only apo A-I remained as an independent predictor in multivariate analyses. All lipid variables except low density lipoprotein cholesterol were related to the risk of revascularization in univariate analyses, but only apo A-I and apo B were independent predictors of such events. Triglycerides were weakly, but not independently, associated with prognosis. Verapamil and metoprolol had differential short-term effects on lipids, with a shift towards a more atherogenic profile in metoprolol treated patients. However, there was no significant impact of the treatment given, or of these treatment effects on the risk of CV events. Results of the present study suggest that apolipoprotein levels were better predictors of CV events than other lipid parameters in patients with stable angina pectoris.
KW - Angina pectoris
KW - Apolipoproteins
KW - Lipoproteins
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=0030778549&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030778549&partnerID=8YFLogxK
U2 - 10.1016/S0021-9150(97)00147-0
DO - 10.1016/S0021-9150(97)00147-0
M3 - Article
C2 - 9395279
AN - SCOPUS:0030778549
VL - 135
SP - 109
EP - 118
JO - Atherosclerosis
JF - Atherosclerosis
SN - 0021-9150
IS - 1
ER -